Company Profile

Affinity Bioreagents Inc (AKA: ABR)
Profile last edited on: 3/8/2019      CAGE: 1DJS2      UEI: QGGGB7KLFVC3

Business Identifier: Monoclonal and polyclonal antibodies, and recombinant proteins for scientific research community
Year Founded
1989
First Award
1998
Latest Award
1998
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4620 Technology Drive Suite 600
Golden, CO 80403
   (303) 278-4535
   affinity@bioreagents.com
   www.bioreagents.com
Location: Single
Congr. District: 07
County: Jefferson

Public Profile

In July 2008, Affinity BioReagents, Inc. (ABR) was acquired by Thermo Fisher Scientific, Inc. ABR-Affinity BioReagents, Inc. had manufactured and distributed monoclonal and polyclonal antibodies, and recombinant proteins for the scientific research community. The company continues to offer cell biology products that include apoptosis, cell adhesion and junctions, structure markers, and cytokines; cell signaling products, such as bioactive peptides, G protein-coupled receptors, kinases, membrane receptors, steroid receptors, and steroids hormones; controls, secondaries, and tags that include blocking peptides and secondary antibodies; and muscle biology, nuclear biology, neurobiology, and stem cell biology products. Also provided are reagents and immunology services.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1998 1 NIH $99,689
Project Title: Generation of Selective Antisera for Immunocytochemistry

Key People / Management

  James Stiehr -- President

  Stuart A Tobet

Company News

There are no news available.